ANXA5 and chronic myelogenous leukemia, BCR-ABL1 positive: The percentages of CD34+/annexin V+ cells specifically induced by imatinib was of 29.2% for the CML-iPSC #1.24 and 10.8% for the CML-iPSC #1.31 indicating partial restoration of imatinib sensitivity in CML-derived CD34+ cells.